need thereof with no or minimal adverse side effects. In one aspect, the present disclosure refers to a pre-filled injection device for prophylactically treating migraine headache comprising a pharmaceutical composition comprising 70 mg or 140 mg of an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, wherein the anti-CGRP receptor antibody comprises a CDRH1 having the sequence of SEQ ID NO:14, a CDRH2 having the sequence of SEQ ID NO:23, a CDRH3 having the sequence of SEQ ID NO:34, a CDRL1 having the sequence of SEQ ID NO:44, a CDRL2 having the sequence of SEQ ID NO:55, and a CDRL3 having the sequence of SEQ ID NO:65, wherein the pharmaceutical composition is to be administered subcutaneously by the device which delivers an injection volume of 1 ml or less. Accordingly, in one example, the present disclosure provides a method for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor antibody or antigen-binding fragment thereof at a dose of about 35 mg to about 210 mg per month. In some examples, the present disclosure provides a method for prophylactically treating a patient for migraine comprising administering to the patient an anti-CGRP receptor antibody or antigen-binding fragment thereof at a dose of about 35 mg to about 210 mg per month.

[0010] In some examples of the methods, the anti-CGRP receptor antibody or binding fragment thereof is administered to the patient at a dose sufficient to reduce the number of monthly migraine headache days experienced by the patient as compared to the number of monthly migraine headache days prior to treatment or the number of monthly migraine headache days experienced by a patient not receiving the anti-CGRP receptor antibody or binding fragment thereof. In some examples, the dose of anti-CGRP receptor antibody or binding fragment thereof administered to the patient is sufficient to reduce the number of monthly migraine headache days in the patient by at least 50% as compared to the number prior to treatment or the number experienced by a patient not receiving the anti-CGRP receptor antibody or binding fragment thereof.

[0011] In certain examples of the methods, the anti-CGRP receptor antibody or binding fragment thereof is administered to the patient at a dose sufficient to reduce the number of monthly migraine headache hours experienced by the patient as compared to the number of monthly migraine headache hours prior to treatment or the number of monthly migraine headache hours experienced by a patient not receiving the anti-CGRP receptor antibody or binding fragment thereof. In certain other examples of the methods, the anti-CGRP receptor antibody or binding fragment thereof is administered to the patient at a dose sufficient to reduce the number of

CLAIMS

What is claimed:

1. A pre-filled injection device for prophylactically treating migraine headache comprising a pharmaceutical composition comprising 70 mg or 140 mg of an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, wherein the anti-CGRP receptor antibody comprises a CDRH1 having the sequence of SEQ ID NO:14, a CDRH2 having the sequence of SEQ ID NO:23, a CDRH3 having the sequence of SEQ ID NO:34, a CDRL1 having the sequence of SEQ ID NO:44, a CDRL2 having the sequence of SEQ ID NO:55, and a CDRL3 having the sequence of SEQ ID NO:65, wherein the pharmaceutical composition is to be administered subcutaneously by the device which delivers an injection volume of 1 ml or less.

2. The pre-filled injection device of claim 1, wherein the device is a syringe.

3. The pre-filled injection device of claim 1, wherein the device is an autoinjector.

4. The pre-filled injection device of any one of claims 1 to 3, wherein the pharmaceutical composition is to be administered subcutaneously by the device at an injection volume of 1 ml.

5. The pre-filled injection device of any one of claims 1 to 3, wherein the pharmaceutical composition is to be administered subcutaneously by the device at an injection volume of 0.5 ml.

6. The pre-filled injection device of any one of claims 1 to 5, wherein the pharmaceutical composition further comprises an acetate buffer, sucrose, and polysorbate.

7. The pre-filled injection device of claim 6, wherein the polysorbate is polysorbate 20 or polysorbate 80.

8. The pre-filled injection device of any one of claims 1 to 7, wherein the anti-CGRP receptor antibody comprises a heavy chain variable region (VH) comprising the sequence of SEQ ID NO:92, and a light chain variable region (VL) comprising the sequence of SEQ ID NO:80.

9. The pre-filled injection device of any one of claims 1 to 8, wherein the anti-CGRP receptor antibody comprises a heavy chain comprising the sequence of SEQ ID NO:105, and a light chain comprising the sequence of SEQ ID NO:123.

10. The pre-filled injection device of any one of claims 1 to 9, wherein the pharmaceutical composition comprises 70 mg of the anti-CGRP receptor monoclonal antibody.

11. The pre-filled injection device of any one of claims 1 to 9, wherein the pharmaceutical composition comprises 140 mg of the anti-CGRP receptor monoclonal antibody.